The clinical development plan is a blueprint that brings a new drug discovery from preclinical development to market approval. It helps to regulate the process of drug discovery, ensuring patient ...
Laboratory assessments — from preclinical research through post-marketing surveillance — determine whether a cell-based therapy for cancer succeeds or fails. “Every developer out there advancing CAR T ...
SAN DIEGO and SUZHOU, China, July 15, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat ...
Nanobiotix global development plan for first-in-class radioenhancer NBTXR3 across several solid tumor indications proceeds as planned with focus on priority pathways in head and neck cancer and ...
There is a low probability of success for immuno-oncology (IO) research. There is a below average likelihood-of-approval rate for oncology, usually 5.3% vs. 7.9% for all indications. The clinical ...
Bari Kowal, Senior Vice President, Development Operations & Portfolio Management at Regeneron Clinical trial innovation is a hot topic, but it’s not a new one. The first fully virtual randomized trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback